Edgewise Therapeutics Inc. Common Stock (EWTX)
Stock · NASDAQ · Health Care
$37.21as of 10/16/2026
Price chart
Active signals
Resistance level
$38.72
Industry
Biotechnology: Pharmaceutical Preparations
EWTX Signal Track Record
How signals performed across all stocks →What EWTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +5.6% | 63% | September 15, 2026 |
| Bollinger Band Breakout | 26 | +0.7% | 54% | September 17, 2026 |
| Bollinger Band Breakdown | 20 | +7.5% | 70% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -2.8% | 50% | November 4, 2025 |
| Any 20-session window (baseline) | +1.8% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 127
- Website
- edgewisetx.com/
Fundamentals
- 1-day range
- $37.24$38.53
- Market cap
- $4.78B
- P/E (trailing)
- —
- P/E (forward)
- -21.03
- EPS (trailing)
- $-1.85
- Dividend yield
- —
- Beta
- 0.38
- Avg. volume
- 1.35M
52-week range
$14.25$48.51
Next earnings: November 5, 2026 · EPS estimate $-0.56confirmed
Forecasts
13 analyst ratings
Buy 84%
Hold 16%
Sell 0%
1-year price forecast
High
$66
+77.4%
Median
$53
+42.4%
Low
$36
-3.3%
Edgewise Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EWTXEdgewise Therapeutics Inc. Common Stock$37.19▼ 2.64%Market cap $4.78BP/E —$14.25$48.51
- INDVIndivior Pharmaceuticals Inc. Common Stock$32.45▼ 3.48%Market cap $4.82BP/E 11.25$23.67$42.81
- DYNDyne Therapeutics Inc. Common Stock$14.25▼ 6.80%Market cap $4.83BP/E —$13.88$27.31
- ACADACADIA Pharmaceuticals Inc. Common Stock$19.12▼ 2.99%Market cap $4.87BP/E 8.79$18.39$30.96
- MANEVeradermics Incorporated Common Stock$108.82▼ 5.43%Market cap $4.54BP/E —$32$136.72
- PBLSParabilis Medicines Inc. Common Stock$22.75▼ 9.65%Market cap $4.23BP/E —$24.51$42.49
- TNGXTango Therapeutics Inc.$22.04▼ 2.91%Market cap $4.19BP/E —$6.69$34.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics Inc. Common Stock | $4.78B | — | $37.19 | ▼ 2.64% | $14.25$48.51 |
| INDV Indivior Pharmaceuticals Inc. Common Stock | $4.82B | 11.25 | $32.45 | ▼ 3.48% | $23.67$42.81 |
| DYN Dyne Therapeutics Inc. Common Stock | $4.83B | — | $14.25 | ▼ 6.80% | $13.88$27.31 |
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.87B | 8.79 | $19.12 | ▼ 2.99% | $18.39$30.96 |
| MANE Veradermics Incorporated Common Stock | $4.54B | — | $108.82 | ▼ 5.43% | $32$136.72 |
| PBLS Parabilis Medicines Inc. Common Stock | $4.23B | — | $22.75 | ▼ 9.65% | $24.51$42.49 |
| TNGX Tango Therapeutics Inc. | $4.19B | — | $22.04 | ▼ 2.91% | $6.69$34.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Ratingbenzinga · 10/16/2026
- Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400Yahoo · 10/8/2026
- Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection FractionBenzinga · 10/8/2026
- Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?Yahoo · 10/3/2026
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Yahoo · 10/2/2026
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesYahoo · 10/1/2026
- Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer SaysYahoo · 9/25/2026
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 TranscriptSeekingAlpha · 9/22/2026
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - SlideshowSeekingAlpha · 9/22/2026
Insider Activity
Insider Actions →Acquired
270.0K
Disposed
11.7K
- Fox Jonathan C · October 1, 2026 · Grant308
- Donovan Joanne M. · August 13, 2026 · Sale2.9K @ $43.41
- Derakhshan Behrad · August 12, 2026 · Sale304 @ $44.5
- Derakhshan Behrad · August 12, 2026 · Sale2.2K @ $43.79
- Nofi Michael · August 12, 2026 · Grant24.4K
- Donovan Joanne M. · August 12, 2026 · Grant32.5K
- Donovan Joanne M. · August 12, 2026 · Option Exercise7.0K
- Donovan Joanne M. · August 12, 2026 · Option Exercise5.8K
- Donovan Joanne M. · August 12, 2026 · Sale800 @ $44.52
- Donovan Joanne M. · August 12, 2026 · Sale104 @ $44.43
- Donovan Joanne M. · August 12, 2026 · Sale2.8K @ $43.71
- MOORE JOHN R · August 12, 2026 · Sale99 @ $44.5
- MOORE JOHN R · August 12, 2026 · Sale59 @ $44.41
- MOORE JOHN R · August 12, 2026 · Sale2.4K @ $43.81
- KOCH KEVIN · August 12, 2026 · Grant200.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 118.11M
- Total value held
- $3.70B
- Institutional holders
- 211
Top holders this quarter
- Unknown15.52M
- Unknown10.43M
- Unknown7.37M
- Unknown6.58M
- Unknown6.47M
- Unknown5.92M
- Unknown5.35M
- Unknown4.48M
- Unknown4.43M
- Unknown4.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.